BioPharma Reporter

DECEMBER 22, 2020

Ajinomoto Bio-Pharma Services and Revance Therapeutics have announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.

Botox 52

Botox Manufacturing Regulation Marketing 52

pharmaphorum

MARCH 18, 2022

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 62

Botox Medicine Nurses Sales 62

pharmaphorum

MARCH 2, 2022

SV2A is an emerging target in neurological diseases, a poorly understood transmembrane glycoprotein that is thought to play a role in regulating the release of neurotransmitter molecules from neurons.

Botox 52

Botox Drugs Regulation Development 52

pharmaphorum

FEBRUARY 12, 2021

In 2020, Allergan opened a global Botox manufacturing facility in Westport, a tourist town on the west coast of Ireland and biotech company Regeneron established a biologic plant in Limerick.

Life Science 123

Life Science Botox Pharma Packaging Regulation 123

The Pharma Data

APRIL 30, 2021

Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 Botox Cosmetic*. Botox Therapeutic*. Global net revenues from the aesthetics portfolio were $1.141 billion , an increase of 34.9 percent on a comparable operational basis.

Botox 40

Botox Production Development Cosmetics 40

The Pharma Data

FEBRUARY 4, 2021

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. – Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million.

Botox 52

Botox Production Sales Cosmetics 52

XTalks

AUGUST 2, 2023

In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. percent increase since 2021, predominantly due to Botox sales for therapeutic uses. Botox is also used as therapeutic treatments for neck spasms, excessive sweating, lazy eyes and migraines.

Sales 98

Sales Manufacturing FDA Approval Life Science 98